Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It has the rights
in the United States, Europe, and Canada to vonoprazan, a potassium competitive acid blocker (P-CAB) in late clinical-stage development for the treatment of gastric acid-related diseases. The company also provides plans to initiate a Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease and the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was formerly known as North Bridge IV, Inc. and changed its name to Phathom Pharmaceuticals, Inc. in March 2019. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois. The company trades on NASDAQ exchange. The company headquarter is located in Buffalo Grove, IL. The company was established in the 2018.
| Ticker | PHAT |
| Long Name | Phathom Pharmaceuticals, Inc. |
| Short Name | Phathom Pharma |